Login / Signup

Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease.

Katharina DörrAlexander KainzRainer Oberbauer
Published in: Current opinion in nephrology and hypertension (2022)
Data from a recent trial of etelcalcetide on LVH suggest that FGF23 may be a possible therapeutic target for cardiac risk reduction in patients on haemodialysis. If these findings are confirmed by further research, it might be speculated that a treatment shift from active vitamin D towards FGF23-lowering therapy may occur in patients on haemodialysis.
Keyphrases